7 Federal Agencies & Big Pharma Quietly Built A Pandemic-Industrial Complex
Authored by Jon Fleetwood via substack,
Nearly 14 years before COVID-19, HHS created the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and centralized federal health, biomedical, regulatory, homeland-security, and military functions around a government-directed countermeasure pipeline.
Creating what this website refers to as the Pandemic-Industrial Complex (PIC).
PHEMCE centralized seven named federal agencies and components (ASPR, CDC, FDA, NIH, DOD, DHS, and VA) across four Cabinet departments: HHS, DOD, DHS, and VA.
Private industry was explicitly inserted into that structure.
HHS named pharmaceutical manufacturers, biotechnology companies, clinical research organizations, and private research organizations.
Then it proposed increasing industry access to HHS agencies, streamlining regulation, lowering obstacles to private investment, and applying liability protections.
The government’s own documents show the same apparatus stretching from threat detection and intelligence assessments through research, product development, regulation, procurement, stockpiling, deployment, and use.
The national-security conflict is obvious.
What happens when the government institutions helping define an alleged biological threat are centralized with the institutions funding research around it, determining what product should be made, regulating that product, buying it, and organizing its deployment?
And what happens if research financed or overseen within the wider biodefense ecosystem contributes to producing the very threat that activates that apparatus?
Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) all acknowledged that the COVID-19 pandemic was “likely” the result of a laboratory incident involving engineered pathogens.
HHS itself warned in 2006 that laboratory-engineered organisms:
That warning makes the conflict much harder to dismiss.
DARPA’s PROPHECY, ADEPT, P3 and PREEMPT programs provide a concrete example of what this PHEMCE architecture looked like inside DOD: military programs moved from predicting alleged viral evolution to sequence-based pharmaceuticals, compressed countermeasure timelines and animal-virus surveillance, while DEFUSE proposed applying that machinery specifically to SARS-related bat coronaviruses.
HHS’s September 8, 2006, draft PHEMCE Strategy states:
HHS then defined the reach of the apparatus:
The government justified this concentration by citing alleged CBRN and biological threats, then demanded:
And under HHS leadership:
HHS also explicitly inserted private industry into the product-development system:
Then:
And one passage reveals what HHS itself counted as a “benefit”:
That is the conflict in plain language.
PHEMCE was not organized solely around whether a product cured disease.
HHS explicitly counted the product’s storage, utilization, and deployment as part of its “benefit.”
The April 2007 implementation plan described the centralized structure this way:
It then names the agencies:
The plan then lays out the threat-to-product sequence.
HHS said medical-countermeasure requirements would incorporate:
and immediately moved to:
for products potentially covering:
Government procurement could then be sized to:
NIH was ordered to align its research with PHEMCE priorities:
And HHS wanted:
The same plan sought technologies permitting:
followed by:
That is the architecture.
Threat designation → intelligence → product requirement → research → industrial development → acquisition → deployment.
The two HHS documents confirm PHEMCE centralized seven named federal agencies and components across four Cabinet departments while explicitly inserting pharmaceutical and biotechnology interests into the same government-directed countermeasure structure.
HHS ordered participants to “align and synchronize,” proposed streamlined regulation, lower barriers and liability protections for private developers, contemplated government financing through clinical trials, and said government purchases could “drive industrial development.”
NIH was ordered to maintain a “sustainable, continuous stream” of products aligned with “future acquisitions.”
And HHS itself acknowledged that laboratory-engineered organisms could be “mistaken as naturally occurring emerging agents.”
In all, the documents reveal the central conflict of the Pandemic-Industrial Complex: the same broader government system can help define an alleged biological threat, finance research around it, determine the product requirements, integrate private industry, influence regulation, create the market through procurement, purchase the resulting products and organize their deployment.
That conflict is no longer merely hypothetical.
A laboratory incident involving coronavirus research is itself a mainstream hypothesis under consideration for the origin of COVID-19.
If COVID-19 resulted from research connected to the same wider U.S.-funded biodefense and pandemic-preparedness ecosystem represented inside this apparatus, the implications would extend far beyond public health: a government-connected research ecosystem could be implicated in causing an international biological catastrophe while interconnected institutions within that wider system possessed roles in assessing its origin, controlling relevant information and intelligence, and directing the resulting countermeasure response.
Who independently investigates the system when the system itself may be implicated?
And if a government-connected research ecosystem can potentially contribute to producing the biological catastrophe, while the wider apparatus can then define the threat, finance the response, create the product requirements, “drive industrial development” and organize deployment, does the resulting emergency expose the system—or give that same system more money, authority, and power?
Tyler Durden Wed, 08/19/2026 - 06:30
Continue reading...
[ H/T ZeroHedge ]
Authored by Jon Fleetwood via substack,
Nearly 14 years before COVID-19, HHS created the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and centralized federal health, biomedical, regulatory, homeland-security, and military functions around a government-directed countermeasure pipeline.
Creating what this website refers to as the Pandemic-Industrial Complex (PIC).
PHEMCE centralized seven named federal agencies and components (ASPR, CDC, FDA, NIH, DOD, DHS, and VA) across four Cabinet departments: HHS, DOD, DHS, and VA.
Private industry was explicitly inserted into that structure.
HHS named pharmaceutical manufacturers, biotechnology companies, clinical research organizations, and private research organizations.
Then it proposed increasing industry access to HHS agencies, streamlining regulation, lowering obstacles to private investment, and applying liability protections.
The government’s own documents show the same apparatus stretching from threat detection and intelligence assessments through research, product development, regulation, procurement, stockpiling, deployment, and use.
The national-security conflict is obvious.
What happens when the government institutions helping define an alleged biological threat are centralized with the institutions funding research around it, determining what product should be made, regulating that product, buying it, and organizing its deployment?
And what happens if research financed or overseen within the wider biodefense ecosystem contributes to producing the very threat that activates that apparatus?
Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) all acknowledged that the COVID-19 pandemic was “likely” the result of a laboratory incident involving engineered pathogens.
HHS itself warned in 2006 that laboratory-engineered organisms:
That warning makes the conflict much harder to dismiss.
DARPA’s PROPHECY, ADEPT, P3 and PREEMPT programs provide a concrete example of what this PHEMCE architecture looked like inside DOD: military programs moved from predicting alleged viral evolution to sequence-based pharmaceuticals, compressed countermeasure timelines and animal-virus surveillance, while DEFUSE proposed applying that machinery specifically to SARS-related bat coronaviruses.
HHS Creates PHEMCE & Orders Government & Industry to ‘Align & Synchronize’
HHS’s September 8, 2006, draft PHEMCE Strategy states:
HHS then defined the reach of the apparatus:
The government justified this concentration by citing alleged CBRN and biological threats, then demanded:
And under HHS leadership:
HHS also explicitly inserted private industry into the product-development system:
Then:
And one passage reveals what HHS itself counted as a “benefit”:
That is the conflict in plain language.
PHEMCE was not organized solely around whether a product cured disease.
HHS explicitly counted the product’s storage, utilization, and deployment as part of its “benefit.”
The 2007 Plan Turns PHEMCE Into an ‘End-to-End’ Threat-to-Product Pipeline
The April 2007 implementation plan described the centralized structure this way:
It then names the agencies:
The plan then lays out the threat-to-product sequence.
HHS said medical-countermeasure requirements would incorporate:
and immediately moved to:
for products potentially covering:
Government procurement could then be sized to:
NIH was ordered to align its research with PHEMCE priorities:
And HHS wanted:
The same plan sought technologies permitting:
followed by:
That is the architecture.
Threat designation → intelligence → product requirement → research → industrial development → acquisition → deployment.
Bottom Line
The two HHS documents confirm PHEMCE centralized seven named federal agencies and components across four Cabinet departments while explicitly inserting pharmaceutical and biotechnology interests into the same government-directed countermeasure structure.
HHS ordered participants to “align and synchronize,” proposed streamlined regulation, lower barriers and liability protections for private developers, contemplated government financing through clinical trials, and said government purchases could “drive industrial development.”
NIH was ordered to maintain a “sustainable, continuous stream” of products aligned with “future acquisitions.”
And HHS itself acknowledged that laboratory-engineered organisms could be “mistaken as naturally occurring emerging agents.”
In all, the documents reveal the central conflict of the Pandemic-Industrial Complex: the same broader government system can help define an alleged biological threat, finance research around it, determine the product requirements, integrate private industry, influence regulation, create the market through procurement, purchase the resulting products and organize their deployment.
That conflict is no longer merely hypothetical.
A laboratory incident involving coronavirus research is itself a mainstream hypothesis under consideration for the origin of COVID-19.
If COVID-19 resulted from research connected to the same wider U.S.-funded biodefense and pandemic-preparedness ecosystem represented inside this apparatus, the implications would extend far beyond public health: a government-connected research ecosystem could be implicated in causing an international biological catastrophe while interconnected institutions within that wider system possessed roles in assessing its origin, controlling relevant information and intelligence, and directing the resulting countermeasure response.
Who independently investigates the system when the system itself may be implicated?
And if a government-connected research ecosystem can potentially contribute to producing the biological catastrophe, while the wider apparatus can then define the threat, finance the response, create the product requirements, “drive industrial development” and organize deployment, does the resulting emergency expose the system—or give that same system more money, authority, and power?
Tyler Durden Wed, 08/19/2026 - 06:30
Continue reading...
[ H/T ZeroHedge ]
